Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 1

Conditions

Stomach Neoplasms 3Urinary Bladder Neoplasms 1Squamous-Cell Non-Small-Cell Lung Cancer 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma 1

Interventions

Oxaliplatin 53Cisplatin 52Fluorouracil 50Capecitabine 48pembrolizumab 39Leucovorin 31Docetaxel 26Trastuzumab 23Paclitaxel 20Irinotecan 20Ramucirumab 13Bevacizumab 12Cetuximab 9Radiotherapy 8Surgical Procedures, Operative 7S 1 (combination) 7Nivolumab 7Epirubicin 7Carboplatin 6olaparib 5Platinum 5Everolimus 5Sunitinib 4Mitomycin 4trastuzumab deruxtecan 3lenvatinib 3epacadostat 3bemarituzumab 3apatinib 3Saline Solution 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Stomach Neoplasms × bemarituzumab × Clear all
NCT02318329 2024-06-04

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Five Prime Therapeutics, Inc.

Phase 1 Completed
79 enrolled 21 charts
GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

NCT03343301 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 1 Completed
12 enrolled 17 charts
Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT03694522 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 2 Completed
155 enrolled 19 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡